Status:

NOT_YET_RECRUITING

Methyl Aminolevulinate 8% and 16% Incubated by 1 and 3 for Actinic Keratoses Treatment

Lead Sponsor:

University of Nove de Julho

Conditions:

Actinic Keratoses

Eligibility:

All Genders

40-90 years

Phase:

NA

Brief Summary

The objective of this protocol is to compare the efficacy of the topical application of MAL at concentrations of 8% and 16%, mediated by red light, as well as to evaluate the impact of different incub...

Detailed Description

The multifocality of actinic keratosis, the unpredictability of lesion evolution with potential progression to squamous cell carcinoma (SCC), and the consequent risk of local extension and metastasis,...

Eligibility Criteria

Inclusion

  • Individuals of both sexes,
  • Aged between 40 and 90 years,
  • Fitzpatrick skin phototypes I to IV,
  • Photodamaged skin with at least five clinically evident actinic keratosis lesions on the face to be treated,
  • No prior treatment for at least six months.

Exclusion

  • Clinically diagnosed infiltrative lesions, as the gold standard treatment is surgical with histopathological evaluation of the lesion (surgery will be performed at no cost to the participant), who will receive guidance and referral for appropriate treatment.
  • Photosensitive diseases, such as systemic lupus erythematosus, dermatomyositis, porphyria, among others.
  • History of arsenic exposure,
  • Known allergy to MAL or similar photosensitizing agents,
  • Psychoactive drug abuse,
  • Previous radiotherapy at the lesion site(s),
  • Participation in another clinical trial,
  • Intense tanning at the time of treatment,
  • Pregnant or breastfeeding women,
  • Local or systemic infection,
  • Immunosuppression: uncompensated chronic diseases or emotional disorders considered contraindications to treatment,
  • Skin conditions on the neck and anterior chest.

Key Trial Info

Start Date :

November 30 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 30 2026

Estimated Enrollment :

144 Patients enrolled

Trial Details

Trial ID

NCT06507644

Start Date

November 30 2024

End Date

May 30 2026

Last Update

October 15 2024

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Methyl Aminolevulinate 8% and 16% Incubated by 1 and 3 for Actinic Keratoses Treatment | DecenTrialz